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•  Ipilimumab has been shown to improve 
overall survival in patients with advanced 
melanoma. 
•  Ipilimumab is a human monoclonal 
antibody that blocks CTLA-4, a protein 
receptor on T cells that results in 
therapeutic upregulation of cytotoxic T 
cells that have anti-tumor effect. 
•  However, ipilimumab can cause immune-
mediated effects that range from mild 
to life-threatening conditions  colitis, 
fulminant hepatitis, nephritis, hypophysitis, 
and toxic epidermal necrolysis.
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•  A 43 year-old Caucasian female with recent diagnosis of malignant melanoma status post 
excision and adjuvant chemotherapy with high dose ipilimumab presented to the hospital with 
three day history of progressively worsening cramping abdominal pain associated with diarrhea. 
•  Initial Abdominal CT (Image 1) showed pancolitis and C-reactive protein (CRP) was elevated at 
70mg/l. 
•  After a negative infectious work, her symptoms were attributed to autoimmune colitis from her 
immunotherapy with ipilimumab. 
•  She was treated with steroids and had rapid resolution of her symptoms and the patient was 
discharged on tapering doses of steroids
•  Two months later, patient presented with recurrent symptoms. 
•  Repeat CT Abdomen (Image 2) showed new inflammatory changes in the stomach and jejunum.
•  Further evaluation with Esophagogastroduodenoscopy (EGD) showed diffuse gastritis and 
duodenitis (Image 3).  
•  Histopathology showed inflammatory gastric mucosa.  
•  Flexible sigmoidoscopy showed diffuse circumferential granular colitis.
•  Treatment with infliximab and high dose steroids resulted in quick resolution of symptoms.
Image 1 Image 2 Image 3
1Department of Internal Medicine, 2Department of Gastroenterology, Lehigh Valley Health Network, Allentown, PA
Abdul Aleem MD1, Anam Malik MD1, Eric Nellis MD2  and Hiral N.Shah MD2 
CASE PRESENTATIONBACKGROUND
Discussion:
•  Ipilimumab causes dysregulation of gastrointestinal (GI) 
mucosal immunity commonly manifesting as immune related 
adverse events ( irAEs )such as colitis but can also involve the 
esophagus, stomach, duodenum and the ileum.
•  There have been many described cases of autoimmune colitis 
secondary to ipilimumab therapy but this case highlights 
the diffuse involvement of the upper and lower GI system 
caused by a single dose of ipilimumab requiring multiple 
hospitalizations and its refractoriness to tapering doses of  
steroids and infliximab. 
Follow-up:
•  The patient is currently maintained on chronic oral steroids 
and budesonide.
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